Pharmac notification of atomoxetine open access and brand switch
Pharmac are pleased to announce a decision on atomoxetine.
Atomoxetine will have all funding restrictions removed from 1 July 2019, and there will be a brand switch to Generic Partners’ brand over a five-month transition period also starting 1 July 2019.
Please see Pharmac's formal notification for more information regarding this decision.
If you have any questions about this decision, please email us at email@example.com or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.